# Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

> **NCT06909253** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 50 (estimated)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT06909253
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909253, "Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06909253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*